Back to search results

A Study of Semaglutide for Obesity

This study is testing a new way to predict how well people with obesity might respond to a medication called semaglutide (2.4 mg given as a shot under the skin once a week). You might be able to join if you are between 18 and 65 years old, have obesity (a BMI of 30 or higher), and haven't had recent major weight changes or bariatric surgery. The study will look at whether a saliva test, called MyPhenome, can help predict if semaglutide will be effective for you. Success in this study means seeing a change in your total body weight after 24 weeks. The current recruitment status is unclear.

Study design
This study is for 135 participants and compares semaglutide to a placebo (a shot that looks like the study drug but has no active ingredient).
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your total body weight will be measured at the beginning of the study and again at 24 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06814938

A Study of a Novel Precision Medicine Approach For Obesity

Active, Not Recruiting
PHASE4Ages 18–65InterventionalTreatment
Mayo Clinic
~135 participants
Updated 2026-07-16 on ClinicalTrials.gov
What's tested:SemaglutidePlacebo

At a glance

Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Total Body Weight at 24 weeks
Measured over Baseline, 24 weeks

Conditions

Obesity

Explore related trials

Obesity

Where it's being run

2 sites across 2 states
Florida1
Minnesota1

Study leadership

  • Andres Acosta, MD, PhD · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Weight changes greater than 3% in the previous 3 months
History of bariatric surgery including lap band and bariatric endoscopy
Significant untreated psychiatric dysfunction based upon screening with the Hospital Anxiety and Depression Inventory (HAD), Questionnaire on Eating and Weight Patterns (binge eating disorders and bulimia) and Columbia Suicide Severity Rating Scale (C-SSRS). If such a dysfunction is identified by an anxiety or depression score \>11 or difficulties with substance or eating disorders, the participant will be excluded and given a referral letter to his/her primary care doctor for further appraisal and follow-up. Any suicidal ideation of type 4 or 5, any suicide attempt during the patient's lifetime, or any suicidal behavior in the last month.
Current use of anti-obesity medications or GLP1R agonists for Type 2 Diabetes
Any contraindication to FDA-approved GLP1R agonists
A person who is pregnant or wanting to become pregnant
Once the positive or negative cohort is filled at 2:1 ratio, some patients will be screen failed if their gene cohort is full.
A family member who is enrolled in this study.
Principal Investigator Discretion

What this trial measures

  • Change in Total Body Weight at 24 weeksBaseline, 24 weeks

    Percent change in body weight in biomarker positive participants vs. biomarker negative participants taking semaglutide vs placebo.